Agios Reports Third Quarter 2016 Financial Results And Reviews Recent Progress In IDH And PKR Development Programs

-   Enasidenib (AG-221) on Track for NDA Submission in IDH2m Positive Relapsed/Refractory AML by Year End -   

                          - Follow-on Offering Raised Approximately $173 Million in September; Updated 2016 Year End Cash Position Expected to be More than $550 Million -                            - Seven Abstracts Accepted for Presentation at ASH, Including Updated Data from AG-348 Phase 2 DRIVE PK, AG-519 Phase 1 Healthy Volunteer and AG-120 Phase 1 Dose Escalation Studies -                            

CAMBRIDGE, Mass., Nov. 03, 2016 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the fields of cancer metabolism and rare genetic metabolic disorders, today reported business highlights and financial results for the third quarter ended September 30, 2016.

"We have made significant progress during 2016, establishing proof of concept with our lead pyruvate kinase-R (PKR) activator, executing late-stage clinical development for both of our lead isocitrate dehydrogenase (IDH) mutant inhibitors in hematologic malignancies and strengthening our balance sheet through our recent financing," said David Schenkein, M.D., chief executive officer at Agios. "As we head into year end, we are focused on supporting the enasidenib NDA submission with our partner Celgene and planning for our next steps in clinical development for our PKR and IDH portfolios based on data we will present at a number of upcoming medical meetings this quarter."

THIRD QUARTER 2016 HIGHLIGHTS & UPDATES

IDH Mutant Inhibitors in Hematologic Malignancies:

In September, Agios and Celgene announced plans to submit a new drug application (NDA) to the U.S. Food and Drug Administration for enasidenib (AG-221) in relapsed and/or refractory (R/R) acute myeloid leukemia (AML) with an IDH2 mutation by year-end. The NDA will be based on data from an ongoing Phase 1/2 trial in patients with relapsed and/or refractory AML and other advanced hematologic malignancies with an IDH2 mutation.

If you liked this article you might like

Celgene, Agios Update Blood Cancer Drug Study Results in ASCO '17 Abstract

4 Health Care Charts Signaling Buys: Pfizer, Amgen Included

These 4 Healthcare Charts Are Signaling Buys

Biotechs Among 5 Stocks Setting Up for Major Breakouts

Analysts' Actions -- Chipotle, Disney, Brinker, JPMorgan and More